Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
18.03 USD | +0.11% | -2.92% | -9.19% |
Apr. 12 | Hashicorp Insider Sold Shares Worth $366,031, According to a Recent SEC Filing | MT |
Apr. 10 | RBC Ups Price Target on Healthpeak Properties to $22 From $21, Keeps Outperform Rating | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company is one of the best yield companies with high dividend expectations.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Weaknesses
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 42.86 and 30.43 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialized REITs
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.19% | 12.78B | A | ||
+0.82% | 53.67B | A- | ||
-14.02% | 17.17B | A- | ||
-1.24% | 7.35B | B | ||
-19.97% | 5.26B | B- | ||
+5.32% | 3.2B | C- | ||
-5.19% | 3.11B | C+ | ||
-7.33% | 3.02B | C | ||
-8.09% | 2.93B | B+ | ||
+9.11% | 2.62B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOC Stock
- Ratings Healthpeak Properties, Inc.